相关实验视频

Updated: Jan 7, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

基于血细胞发育的预测预后和治疗反应在个体多发性髓瘤

Sitao Jiang¹, Yuan Yang¹, Man Yao¹

¹Department of Biology, Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, School of Life Sciences, Beijing Normal University, Beijing, 100875, China.

Frontiers of medicine

|December 17, 2025

概括

一个新的骨髓瘤分类评分 (MCS) 使用基因表达来预测多发性骨髓瘤 (MM) 患者的预后和治疗反应. 这一分数提供了独立于现有模型的个性化风险分层.

科学领域:

基因组学就是基因组学.
在瘤学瘤学.
生物标志物发现发现

背景情况:

多发性髓瘤 (MM) 呈现出显著的临床异质性.
了解MM病变的基因网络融合对于个性化医学至关重要.

研究的目的:

开发一种基于基因表达的新型生物标志物,用于MM的风险分层和治疗反应预测.
在多种MM患者队列中评估骨髓瘤分类得分 (MCS) 的有用性.

主要方法:

将MCL1和TLR10基因模块的相互表达模式转化为MCS.
在1738名新诊断的MM (NDMM) 和319名复发/耐药MM (RRMM) 患者的多个队列和试验中验证了MCS.
评估MCS用于预后,疾病状态歧视和对博尔特佐米布和卡菲尔佐米布治疗的反应预测.

主要成果:

在NDMM和RRMM患者中,MCS显示出预后能力.
MCS有效地区分了渐进和稳定的疾病状态.
独立于现有模型,MCS预测了对博尔特佐米布和卡菲尔佐米布的治疗反应.
通过MCS定义的风险组显示出不同的可向途径.

结论:

骨髓瘤分类得分 (MCS) 是一个强大的,个性化的MM生物标志物.
在MM患者中,MCS增强了风险分层和治疗响应预测.
MCS为个性化MM管理提供了当前预后模型的替代方案.

关键词:

个性化分子亚型的个性化分子亚型.多发性骨髓瘤是多发性骨髓瘤的一种.蛋白酶体抑制剂是一种蛋白酶体抑制剂.风险分层的分层化治疗对治疗的反应反应.

更多相关视频

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

相关概念视频

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...